Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Early Liver Cancer Detection through Glycolytic Genes

Page View:

The advantages of early detection in cancer screening cannot be overstated. Mountains of evidence exist showing the importance of intervening quickly not only to halt the spread of disease but also that survival rates improve dramatically for nearly all forms of cancer. Yet, identifying early markers of cancer remains a challenge for scientists. Although now, investigators at Brunel University London and the University of Leeds have just published new evidence that could offer hope for identifying liver cancer in its early stages.

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Unfortunately, however, most cases are discovered too late for a cure. The results from this new study show a dramatic increase in the expression of glycolytic enzymes in precancerous cirrhotic livers. This increase is associated with a significantly higher risk of developing hepatocellular carcinoma (HCC) – the main type of liver cancer – and could lead to a biomarker which identifies those at risk of malignancy.

Early Liver Cancer Detection through Glycolytic Genes

Findings from the new study were published in Frontiers in Cell and Developmental Biology through an article titled “High Expression of Glycolytic Genes in Cirrhosis Correlates with the Risk of Developing Liver Cancer.”

“We know that 90% of all hepatocellular carcinoma cases start with liver cirrhosis,” explains study investigators Salvatore Papa, Ph.D., an academic fellow at the University of Leeds and Concetta Bubici, Ph.D., a lecturer at Brunel University London. “So, by pinpointing when cirrhosis progresses to cancer, we could improve early detection and treatment – with surgery, chemo, and radiotherapy, but perhaps also with new treatments which reverse the transition.”

In the field of metabolic diseases, Medicilon has a portfolio of stable and effective animal models, including for Non-alcoholic Fatty Liver Disease (NAFLD), obesity and diabetes.

In cirrhosis, chronic damage caused by hepatitis viruses B or C, alcohol, or obesity leads to scarring and formation of regenerative nodules in the liver. High cell turnover in these nodules, with an accumulation of genetic damage, can eventually produce cancerous cells.

“We set out to find features of cirrhotic cells that might predict cancerous change,” Dr. Papa notes.

For nearly a century, scientists have recognized that cancer cells shift the way they generate energy. Normally the body obtains energy from macronutrients – sugars, fats, proteins, and their intermediaries – primarily using oxygen. But our cells can also extract energy from sugars without using oxygen. This anaerobic process, called glycolysis, produces the lactate that “burns” our muscles during intense exercise – and is also used by cancers to fuel their rampant growth.

“Like virtually all cancers, highly-proliferating HCC cells seem to readjust their energy metabolism towards glycolysis, irrespective of oxygen availability,” Dr. Papa comments. The cause for this shift, known as the Warburg effect – is still unknown, but many researchers believe the inflammatory response is a factor. “Given that cirrhosis is an inflammatory process, we decided to look at whether the metabolic shift to glycolysis is present already in cirrhotic cells – and whether this predicts progression to hepatocellular carcinoma.”

In the current study the researchers analyzed normal, cirrhotic, and cancerous (HCC) liver samples from patients followed up over ten years following a liver biopsy.

“To have a complete overview of energy metabolism changes in HCC and premalignant stages of disease, we measured the expression of genes encoding enzymes involved in glycolysis and other metabolic pathways,” Dr. Papa states.

The research team found that glycolysis-related genes – including hexokinase 2 (HK2), aldolase A (ALDOA), and pyruvate kinase M2 (PKM2) – are highly expressed not only in HCC but also in cirrhosis as compared to normal liver samples.

“In other words: the shift to glycolysis occurs in the precancerous stage,” Dr. Bubici remarks.

Interestingly, the level of expression of glycolysis-related genes showed a positive correlation with the progression of cirrhosis to HCC – and with poor outcome in those with HCC already at the time of biopsy.

“This suggests expression of glycolytic enzymes could be used as a new biomarker to predict the risk of later development of HCC in patients with cirrhosis,” Dr. Bubici notes.

While the investigators were excited by their findings, they did stress that their study was preliminary, and more work needs to be done.

“Further studies are needed to establish whether these changes in gene expression are borne out as changes in glycolytic activity,” the authors commented.

Still, the findings reveal a promising means to improve HCC survival through early detection and treatment. According to Dr. Papa, the shift to a glycolytic expression profile in cirrhotic cells could even be a target for new HCC therapies.

“For example, clinical trials are currently underway to explore the effect of statins – which are used to help prevent cardiovascular disease – on HCC development in cirrhotic patients or HCC recurrence following surgical removal,” Dr. Papa concludes. “It is very likely that by blocking cholesterol synthesis, statins would also suppress glycolysis as these chemical pathways overlap. If these trials show that statins reduce HCC risk, further studies would be necessary to establish whether the inhibition of glycolysis in cirrhotic cells is responsible.”

Relevant newsRelevant news